Introduction
Use of patient-centric monitoring approaches to evaluate therapies such as vedolizumab (VDZ) are gaining momentum to optimize disease outcomes in patients with Crohn’s disease (CD). Transmural healing, assessed by intestinal ultrasonography (IUS), is an emerging outcome, enabling frequent non-invasive evaluation of CD. There is limited real-world evidence on the effectiveness of current treatments for induction and maintenance of a transmural response to inform treatment decisions.
Aims & Methods
The SUNRISE study aimed to describe patients with CD treated with VDZ achieving a composite outcome of complete remission and transmural response, utilizing IUS. SUNRISE was an observational, prospective study (NCT05192863) conducted across 10 sites in Canada, Israel and Italy. Adults with moderately to severely active CD, with a bowel wall thickness [BWT] of >3 mm (measured by IUS) and who newly started intravenous VDZ were eligible. The primary objective was to describe the proportion of patients achieving complete remission at month 12, defined as a composite endpoint of corticosteroid-free (Harvey–Bradshaw Index <5 without concomitant corticosteroids) clinical, biochemical (normalization of C-reactive protein and faecal calprotectin) and transmural (BWT <3 mm for all bowel segments without complications [measured by IUS]) remission. Secondary outcomes after VDZ induction were reported at weeks 10 and 14 and months 6, 12 and 18, and included transmural response (≥25% BWT reduction or absolute BWT ≤3 mm for all bowel segments). Health-related quality of life (measured by the Short Inflammatory Bowel Disease Questionnaire [SIBDQ]), patient satisfaction with IUS and treatment patterns were reported.
Results
Overall, 70 patients were eligible for inclusion; median (quartiles 1–3 [Q1–3]) age was 50.0 (39.0–67.0) years, time since CD diagnosis was 4.0 (0.9–17.2) years and treatment duration was 16.5 (9.0–18.6) months. Among 33 patients with complete evaluable data for the primary endpoint, 7/33 (21.2%) achieved complete remission at month 12 after starting VDZ. Among secondary outcomes at month 12, transmural remission or response was achieved by 13/49 patients (26.5%) and 19/49 (38.8%), respectively. Biochemical remission was achieved in 19/38 patients (50.0%) and corticosteroid‑free clinical remission in 34/48 (70.8%) at month 12. Corresponding data across all time points are shown in the Table. Median (Q1–3) SIBDQ total score was 4.3 (3.7–5.6) at baseline, 5.0 (4.4–6.1) at month 6 and 5.5 (4.5–6.3) at month 12. At month 12, 26/32 patients (81.3%) ranked IUS as their preferred test vs colonoscopy, magnetic resonance enterography or computed tomography enterography. VDZ maintenance treatment changes at month 12 included 15 patients (21.4%) discontinuing treatment, 11 (15.7%) switching to subcutaneous VDZ and 2 (2.9%) skipping at least one VDZ dose.
Conclusion
The SUNRISE study provides real-world evidence that VDZ can induce transmural healing in CD. Integration of IUS, a patient-preferred and non-invasive modality, may allow regular monitoring of transmural healing and support treat-to-target strategies in routine care.
This study and medical writing support was funded by Takeda Pharmaceuticals International AG, Zurich, Switzerland.
n/N (%)a
| Week 10 (±1 week)
| Week 14 (±1 week)
| Month 6 (±4 weeks)
| Month 12 (±4 weeks)
| Month 18 (±4 weeks)
|
|---|
Complete remission Corticosteroid-free clinical remission Biochemical remission Transmural remission
| 0/3 (0) 18/32 (56.3) 1/6 (16.7) 2/17 (11.8)
| 1/9 (11.1) 32/53 (60.4) 9/10 (90.0) 5/41 (12.2)
| 4/23 (17.4) 37/53 (69.8) 15/25 (60.0) 12/48 (25.0)
| 7/33 (21.2) 34/48 (70.8) 19/38 (50.0) 13/49 (26.5)
| 3/20 (15.0) 26/40 (65.0) 8/23 (34.8) 10/37 (27.0)
|
Clinical response
| 10/22 (45.5)
| 21/37 (56.8)
| 19/34 (55.9)
| 21/34 (61.8)
| 17/30 (56.7)
|
Transmural response
| 5/17 (29.4)
| 9/41 (22.0)
| 20/48 (41.7)
| 19/49 (38.8)
| 13/37 (35.1)
|
| aNumerator is the number of patients with remission/response; denominator is the number of patients with available data at the time points considered. |
Disclosure
D.C. has received speaker’s fees from AbbVie, Janssen, Reckitt Benckiser and Takeda, research support AbbVie, Janssen, Reckitt Benckiser and Takeda, and consultancy fees from AbbVie, Reckitt Benckiser, Takeda and Taro.
G.F. has received personal fees from AbbVie, Abivax, AlfaSigma, Celltrion, Ferring, Galapagos, Janssen, Lilly, Pfizer, Sandoz, STADA and Takeda.
P.B. is an employee and stockholder of Takeda Pharmaceuticals International AG, Zurich, Switzerland.
F.C. is an employee of the contract research organization IQVIA Solutions Italy s.r.l., hired by Takeda Pharmaceuticals International AG for the following activities: project and site management, data management, quality control and statistical analysis.
S.Ø. is an employee and stockholder of Takeda Pharmaceuticals International AG, Zurich, Switzerland.
K.L.N. has received advisory board fees from AbbVie, Bristol Myers Squibb, Celltrion, Ferring, Janssen and Pfizer, and speaker’s fees and research support from AbbVie, Janssen and Pfizer.
U.K. has received advisory and speaker’s fees from AbbVie, Bristol Myers Squibb, Celltrion, Janssen, Medtronic, Pfizer and Takeda, and research support from Janssen, Medtronic and Pfizer.